• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

Georgiamune and Verily Partner to Advance Novel Cancer Treatment

by Jasmine Pennic 10/26/2023 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know:

– Georgiamune, a privately held, clinical stage biotechnology company, and Verily, an Alphabet precision health technology company forms a strategic partnership to advance novel therapeutics for patients with cancer.

– Through this partnership, Verily and Georgimune will focus on identifying the patient population that could potentially benefit the most from Georgiamune’s GIM-122, a first-in-class dual-functioning antibody that has the potential to help patients with advanced solid tumors who have not responded to current treatments with a checkpoint inhibitor.

Integrating Clinical Trial Data and Longitudinal Real-World Data Sources

The two companies will also focus on driving more efficient clinical development by incorporating clinical trial data and longitudinal real-world data sources. The collaboration innovates how clinical trials are currently conducted by bringing together different data modalities to identify the patient populations most likely to benefit from Georgiamune’s novel therapy and by providing a more holistic analysis of how participants are responding to the therapy over time.

The partners will implement immune mapping with Verily’s Immune Profiler for GIM-122, a first-in-class dual-functioning antibody currently being evaluated for safety, tolerability, and antitumor activity in a first-in-human, phase 1/2 clinical trial in adults with checkpoint refractory or resistant advanced solid tumor malignancies. Georgiamune will utilize Immune Profiler to assess the pharmacodynamic effect of GIM-122 and interrogate the immune response of patients. As part of the partnership, the two companies will also aim to expand into other assets developed by Georgiamune in cancer and other therapeutic areas, including autoimmune diseases. 

“Georgiamune is a cutting edge innovation company with groundbreaking scientific discoveries leading to first and best in class immune therapies for cancer and autoimmune diseases,” said Georgiamune’s Founder and Chief Executive Officer Dr. Samir N. Khleif. “Verily’s expertise in immune profiling, real-world data, and advanced analytics provide a comprehensive data profile to accelerate development of our novel drug candidate. This partnership will allow us to focus on identifying the patient population that could potentially benefit the most from our breakthrough discoveries.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Oncology

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

Digital Health Funding Q3 2025: Choppy Undercurrents Beneath a Steady Surface

Featured Interview

ConcertAI VP Shares View on AI Hallucinations and the Fabricated Data Crisis in Scientific Publishing

Most-Read

Qualtrics Acquires Press Ganey Forsta for $6.75B to Create the Most Comprehensive AI Experience Platform

Qualtrics Acquires Press Ganey Forsta for $6.75B to Create the Most Comprehensive AI Experience Platform

Pfizer and Trump Administration Announce Landmark Agreement to Lower Drug Costs

Pfizer and Trump Administration Announce Landmark Agreement to Lower Drug Costs

KLAS Report: Epic's Native Ambient Speech Tool Reshapes Customer AI Strategies

KLAS Report: Epic’s Native Ambient Speech Tool Reshapes Customer AI Strategies

Epic Unveils MyChart Central and New APIs to Advance Interoperability at Open@Epic

Epic Outlines Roadmap for Next-Generation Data Sharing at Open@Epic

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

RevSpring to Acquire Kyruus Health, Creating a Unified Patient Experience

RevSpring to Acquire Kyruus Health, Creating a Unified Patient Experience

Oracle Confirms Layoffs in Kansas City

Oracle Confirms Layoffs in Kansas City

Philips Future Health Index 2025: AI and Digital Tech Can Help Solve Cardiac Care Crisis

Philips Future Health Index 2025: AI and Digital Tech Can Help Solve Cardiac Care Crisis

Optain Health Secures $26M to Advance AI-Powered Retinal Screening

Optain Health Secures $26M for AI-Powered Retinal Screening

Sutter Health and Epic Launch "Sutter Sync" to Optimize Remote Chronic Care

Sutter Health and Epic Launch “Sutter Sync” to Optimize Remote Chronic Care

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Op-Ed Submission Guidelines
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |